Trastuzumab‐related cardiotoxicity in patients with nonlimiting cardiac comorbidity-Reference-Cited by-同舟云学术

Trastuzumab‐related cardiotoxicity in patients with nonlimiting cardiac comorbidity

Published:2019-04 Issue:3 Volume:25 Page:444-449
ISSN:1075-122X
Container-title:The Breast Journal
language:en
Short-container-title:Breast J

Author:

Martinello Rossella¹,Becco Paolo²,Vici Patrizia³,Airoldi Mario⁴,Del Mastro Lucia⁵,Garrone Ornella⁶,Barone Carla⁷,Pizzuti Laura³,D’Alonzo Alessia⁵,Bellini Elisa⁴,Milani Andrea²,Bonzano Alessandro⁸,Montemurro Filippo²^ORCID

Affiliation:

1. Medical Oncology Cardinal Massaia Hospital Asti Italy

2. Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS Turin Italy

3. Medical Oncology B Regina Elena National Cancer Institute Rome Italy

4. Medical Oncology 2 AOU Citta' della Salute e della Scienza Turin Italy

5. Medical Oncology IRCCS AOU San Martino ‐ IST Genova Italy

6. Medical Oncology S. Croce e Carle Teaching Hospital Cuneo Italy

7. Medical Oncology S. Lorenzo Hospital Carmagnola, Turin Italy

8. Cardiology Candiolo Cancer Institute, FPO‐ IRCCS Turin Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Hindawi Limited

Subject

Oncology,Surgery,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/tbj.13240

Reference23 articles.

1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability‐adjusted life‐years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study;Fitzmaurice C;JAMA Oncol,2016

2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene

3. The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy

4. Development program for the Japanese version of the PRO‐CTCAE;Yamaguchi T;J Patient Rep Outcomes,2013

5. Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect;Pharmacological Research;2024-02

2. Atrial fibrillation induced by anticancer drugs and underling mechanisms;Journal of Cardiovascular Pharmacology;2021-11-17

3. The Efficacy and Safety of Additional Anti-HER2-Targeting Drugs in the Treatment of HER2-Positive Advanced Breast Cancer: A Meta-Analysis;Anti-Cancer Agents in Medicinal Chemistry;2021-07-26

4. Trastuzumab increases pulmonary vein arrhythmogenesis through modulating pulmonary vein electrical and conduction properties via phosphatidylinositol 3-kinase signaling;IRAN J BASIC MED SCI;2020

5. Heart rhythm and conduction disorders as manifestations of cardiotoxicity of anticancer treatment: myth or reality?;The Siberian Medical Journal;2020-04-12